129 related articles for article (PubMed ID: 38012986)
1. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Wang K; Du R; Myall NJ; Lewis WE; Uy N; Hong L; Skoulidis F; Byers LA; Tsao A; Cascone T; Pozadzides J; Tu J; Negrao MV; Gibbons DL; Park K; Rinsurongkawong W; Lee JJ; Gandara D; Behl D; Shu CA; Riess JW; Baik C; Wakelee HA; Vaporciyan AA; Heymach JV; Zhang J; Le X
J Thorac Oncol; 2024 Mar; 19(3):500-506. PubMed ID: 38012986
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
[TBL] [Abstract][Full Text] [Related]
3. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH; Kim SY; Aredo JV; Feng J; Shepherd F; Xu C; Kaldas D; Gray JE; Dilling TJ; Neal JW; Wakelee HA; Liu Y; Lin SH; Abuali T; Amini A; Nie Y; Patil T; Lobachov A; Bar J; Fitzgerald B; Fujiwara Y; Marron TU; Thummalapalli R; Yu H; Owen DH; Sharp J; Farid S; Rocha P; Arriola E; D'Aiello A; Cheng H; Whitaker R; Parikh K; Ashara Y; Chen L; Sankar K; Harris JP; Nagasaka M; Ayanambakkam A; Velazquez AI; Ragavan M; Lin JJ; Piotrowska Z; Wilgucki M; Reuss J; Luders H; Grohe C; Baena Espinar J; Feiner E; Punekar SR; Gupta S; Leal T; Kwiatkowski DJ; Mak RH; Adib E; Naqash AR; Goldberg SB
J Thorac Oncol; 2024 Jun; 19(6):928-940. PubMed ID: 38278303
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].
Wang J; Chi Y; Chen H; Jia B; Zhai X; Ma M; Li J; Zhuo M
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):493-500. PubMed ID: 35899447
[TBL] [Abstract][Full Text] [Related]
5. Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for
Gibson AJW; Dean ML; Litt I; Box A; Cheung WY; Navani V
Curr Oncol; 2024 Apr; 31(5):2427-2440. PubMed ID: 38785463
[No Abstract] [Full Text] [Related]
6. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Okahisa M; Udagawa H; Matsumoto S; Kato T; Yokouchi H; Furuya N; Kanemaru R; Toyozawa R; Nishiyama A; Ohashi K; Miyamoto S; Nishino K; Nakamura A; Iwama E; Niho S; Oi H; Sakai T; Shibata Y; Izumi H; Sugiyama E; Nosaki K; Umemura S; Zenke Y; Yoh K; Kah Mun Low G; Zhuo J; Goto K
Lung Cancer; 2024 May; 191():107798. PubMed ID: 38669727
[TBL] [Abstract][Full Text] [Related]
8. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
Chen CY; Wang GS; Wei JC
J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
[No Abstract] [Full Text] [Related]
9. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Shah V; McNatty A; Simpson L; Ofori H; Raheem F
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
[TBL] [Abstract][Full Text] [Related]
10. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
11. Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.
Matsuura H; Higo H; Kuribayashi T; Tamaoki A; Nakasuka T; Uno M; Makimoto G; Ninomiya K; Fujii M; Rai K; Ichihara E; Hotta K; Miyahara N; Tabata M; Maeda Y; Kiura K; Ohashi K
Thorac Cancer; 2024 Jun; 15(17):1390-1394. PubMed ID: 38698706
[TBL] [Abstract][Full Text] [Related]
12. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
[TBL] [Abstract][Full Text] [Related]
13. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Maione P; Salvi R; Gridelli C
Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
[TBL] [Abstract][Full Text] [Related]
14. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
[TBL] [Abstract][Full Text] [Related]
15. Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.
Petrini I; Giaccone G
Onco Targets Ther; 2022; 15():1197-1210. PubMed ID: 36246734
[TBL] [Abstract][Full Text] [Related]
16. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
18. Amivantamab for the treatment of
Vyse S; Huang PH
Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
[TBL] [Abstract][Full Text] [Related]
19. Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating
Christopoulos P; Girard N; Proto C; Soares M; Lopez PG; van der Wekken AJ; Popat S; Diels J; Schioppa CA; Sermon J; Rahhali N; Pick-Lauer C; Adamczyk A; Penton J; Wislez M
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001589
[TBL] [Abstract][Full Text] [Related]
20. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
